Baidu
map

老年医学

订阅

MedSci主页 / 所有栏目 / 老年医学

2019年AAO：新型的蛋白质治疗剂DARPin®治疗AMD的后期数据

2019-10-05 Allan MedSci原创

DARPin®AMD新型的蛋白质治疗剂
关注

新型的蛋白质治疗剂DARPin®治疗AMD的后期数据将在加利福尼亚州旧金山举行的美国眼科学院（AAO）年会被详细介绍。

新型的蛋白质治疗剂DARPin®治疗AMD的后期数据将在加利福尼亚州旧金山举行的美国眼科学院（AAO）年会被详细介绍。DARPin®是一类新型的蛋白质治疗剂，为多特异性和多功能性AMD治疗开辟了新的维度。

DARPin®治疗剂可以结合五个以上的靶标，与传统的单克隆抗体或目前可用的其他蛋白质治疗剂相比，具有潜在优势。由于DARPin®治疗剂的免疫原性低，在血液和眼睛中的半衰期长，因此有潜力推动现代医学的发展，并显著改善严重疾病的治疗，包括癌症和威胁视力的疾病。DARPin®的开发公司Molecular Partners正在与Allergan公司合作，以推进眼科临床计划。


原始出处：

http://www.firstwordpharma.com/node/1671753#axzz61Rlned4y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (23)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-12-02 lishizhe

    #RPI#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-03-08 remwd

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-03-25 柳叶一刀

    #白质#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-03-07 Boyinsh

    #新型的蛋白质治疗剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-06-17 listen331

    #DARPin®#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-09-19 yinhl1978

    #AAO#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-13 如意如意如我心意

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-12 一个字-牛

    学习了谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-12 1ddf0692m34(暂无匿称)

    学习了，谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1943448, encodeId=be6c1943448aa, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Dec 02 07:15:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380219, encodeId=515c38021994, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VGbg1PhNF6ZI2VxWicqxz7droWMAJsdvfMEicHAyiarJmmVd8LKyUoNIy8zc8Eh4QfrM1qakdBsicXoy28xudkibpnw/132, createdBy=80a195077, createdName=remwd, createdTime=Sun Mar 08 22:44:15 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765799, encodeId=7ccf1e65799c5, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 25 16:15:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769432, encodeId=e1f51e6943298, content=<a href='/topic/show?id=4e9b58264ce' target=_blank style='color:#2F92EE;'>#新型的蛋白质治疗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58264, encryptionId=4e9b58264ce, topicName=新型的蛋白质治疗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5638056375, createdName=Boyinsh, createdTime=Sat Mar 07 16:15:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778455, encodeId=fdd41e7845537, content=<a href='/topic/show?id=511f5e05f3' target=_blank style='color:#2F92EE;'>#DARPin®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5705, encryptionId=511f5e05f3, topicName=DARPin®)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34939244164, createdName=listen331, createdTime=Wed Jun 17 14:15:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071238, encodeId=bbd920e123844, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Sep 19 18:15:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373829, encodeId=62593e382920, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a573355374, createdName=如意如意如我心意, createdTime=Sun Oct 13 00:41:34 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373824, encodeId=c6af3e38249b, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Oct 12 20:44:25 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373810, encodeId=f2443e38109c, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 12 12:30:38 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373800, encodeId=711f3e380052, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Oct 12 08:22:15 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-12 一天没事干

    很好的学习机会

    0

以上为热门评论，梅斯医学App还有更多内容
Baidu
map
Baidu
map
Baidu
map